All patients (1127 pts) | Donors < 50 yrs. (339 pts) | Donors 50–69 yrs. (496 pts) | Donors ≥70 yrs. (292 pts) | P value | |
---|---|---|---|---|---|
1A - Donor characteristics | |||||
M/F (%) | 578/549 (51/49) | 215/124 (63/37) | 229/267 (46/54) | 134/158 (46/54) | < 0,01 |
eGFR CG (ml/min) | 99,38 | 126,89 ± 40,65 | 94,68 ± 34,83 | 76,78 ± 28,22 | < 0,01 |
eGFR CKD-EPI(ml/min) | 83,65 | 103,51 ± 30,39 | 85,79 ± 25,38 | 79,7 ± 22,03 | < 0,01 |
Hypertension (%) | 511 (49) | 66 (21) | 259 (57) | 186 (68) | < 0,01 |
Diabetes mellitus (%) | 78 (8) | 9 (3) | 49 (12) | 20 (8) | < 0,01 |
Cerebrovascular cause of death (%) | 747 (72) | 159 (52) | 370 (80) | 218 (81) | < 0,01 |
1B - Recipient characteristics | |||||
M/F (%) | 721/406 (64/36) | 217/122 (64/36) | 305/191 (61/39) | 199/93 (68/32) | 0,18 |
Mean age (Yrs) | 59.17 ± 9.43 | 43,99 ± 10,69 | 55,31 ± 9,66 | 62,73 ± 7,93 | < 0,01 |
1st Tx/ More than 1 Tx (%) | 972/155 (87/13) | 277/62 (82/18) | 427/69 (86/14) | 268/24 (92/8) | < 0,01 |
SKT/DKT (%) | 1082/45 (96/4) | 339/0 (100/0) | 481/15 (97/3) | 262/30 (90/10) | < 0,01 |
HD/PD (%) | 873/ 308 (79/28) | 279/73 (86/22) | 390/136 (80/28) | 204/99 (71/35) | < 0,01 |
Pretransplant DM 1 or 2/type 2 (%) | 95/79 (10,2/7) | 19/14 (6/4) | 48/35 (10/7) | 16/30 (16/11) | < 0,01 |
Pretransplat Hypertension (%) | 939 (86) | 267 (81) | 420 (88) | 252 (91) | < 0,01 |
Pretransplant Cardiopathy (%) | 358 (32) | 90 (26) | 164(33) | 104 (36) | < 0,01 |
Pretransplant HCV POS (%) | 91 (8) | 26 (8) | 44 (9) | 21 (8) | 0,78 |
1C - Transplant characteristics | |||||
HLA A/B/DR MM (0–2/3–4/5–6) % | 48/46/6 | 32/62/6 | 34/57/9 | 42/54/4 | 0,27 |
PRA zero (CDC) at transplantation % | 66,3 | 63 | 63 | 75,4 | 0,13 |
Cold ischemia time (hours) | 16,16 ± 5,22 | 15,89 ± 5,37 | 17,80 ± 4,98 | 18,25 ± 4,64 | 0,03 |
DGF (%) | 298 (28) | 74 (23) | 135 (29) | 89 (32) | 0,04 |
Induction Therapy | < 0,01 | ||||
ATG (%) | 21 (2) | 3 (1) | 3 (1) | 9 (3) | |
Basiliximab (%) | 1080 (98) | 319 (98) | 479 (98) | 282 (99) | |
Mantaining Therapy | < 0,01 | ||||
Tacrolimus (%) | 848 (79) | 286 (87) | 360 (77) | 202 (73) | |
Cyclosporine (%) | 181 (17) | 32 (10) | 95 (20) | 54 (20) | |
mTORi (%) | 83 (8) | 27 (11) | 31 (7) | 25 (9) | |
mTORi at 1 yr(%) | 169 (15) | 77 (23) | 59 (12) | 33 (11) | < 0,01 |
ACE/ARB (%) | 368 (33) | 190 (56) | 117 (24) | 61 (21) | < 0,01 |
End f-up Mantaining Therapy (%) | < 0,01 | ||||
Tacrolimus (%) | 839 (78) | 271 (83) | 374 (79) | 194 (69) | |
Cyclosporine (%) | 133 (12) | 27 (8) | 64 (13) | 42 (15) | |
mTORi (%) | 255 (24) | 56 (17) | 124 (26) | 73 (26) |